ReviewLife (Basel, Switzerland)2021
Blood Stream Infections from MDR Bacteria.
Review in Life (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 35 citations in OpenAlex.
- A rapid, inexpensive diagnostic for bacterial pathogen and resistance detection in resource-limited settings.Science advances · 2026Article
- Comment on: Changes in microbiological characteristics of bloodstream infections before and after the COVID-19 pandemic in a tertiary teaching hospital in Iran.BMC infectious diseases · 2026Article
- Targeting bacitracin resistance-associated histidine kinase (BraS) in MRSA with isatin and indazole derivatives.Scientific reports · 2026Article
- Risk factors for carbapenem-resistant Acinetobacter baumannii infection in children and A. baumannii-related mortality in the PICU: a retrospective study in Guangxi, China.BMC infectious diseases · 2026Article
- Precise species identification and whole-genome sequencing analysis ofMicrobiology spectrum · 2026Article
- First report on the biological characteristics of carbapenem-resistantFrontiers in cellular and infection microbiology · 2026Article
- Changes in microbiological characteristics of bloodstream infections before and after the COVID-19 pandemic in a tertiary teaching hospital in Iran.BMC infectious diseases · 2025Article
- Exploring the impact of comorbidities and drug resistance on mortality in ICU-acquired bloodstream infections.AMB Express · 2025Article
- Antimicrobial Investigation of Phthalimide andLife (Basel, Switzerland) · 2025Article
- Clinical Characteristics and Independent Risk Factors for Multidrug-ResistantInfection and drug resistance · 2025Article
- Clinical diagnostic value of metagenomic next-generation sequencing in patients with acute infection in emergency department.Heliyon · 2024Article
- Medical Device-Associated Infections Caused by Biofilm-Forming Microbial Pathogens and Controlling Strategies.Antibiotics (Basel, Switzerland) · 2024Review
- Inflammaging in Multidrug-Resistant Sepsis of Geriatric ICU Patients and Healthcare Challenges.Geriatrics (Basel, Switzerland) · 2024Review
- Epidemiology, Clinical, and Microbiological Characteristics of Multidrug-Resistant Gram-Negative Bacteremia in Qatar.Antibiotics (Basel, Switzerland) · 2024Article
- Evaluation of Blood Culture Results in Patients with Malignancy in Erzurum Province, Turkey.Acta medica Lituanic · 2024Article
- Characterization of NDM-5-ProducingGenes · 2023Article
- Article
- Intravenous Fosfomycin: A Potential Good Partner for Cefiderocol. Clinical Experience and Considerations.Antibiotics (Basel, Switzerland) · 2022Article
- Bacterial effluxome as a barrier against antimicrobial agents: structural biology aspects and drug targeting.Tissue barriers · 2022Review
- Cefiderocol for Carbapenem-Resistant Bacteria: Handle with Care! A Review of the Real-World Evidence.Antibiotics (Basel, Switzerland) · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBloodstream infections (BSIs) constitute a growing public health concern, are among the most severe nosocomial pathologies, and are considered a worldwide cause of unfaithful outcomes, increasing treatment costs and diagnostic uncertainties. BSIs are one of the most frequent lethal conditions that are managed in intensive care units (ICUs). In the case of septic shock, immune deficiency, and delayed treatment, even with adequate antimicrobial therapy and/or source control, the outcomes are often unfavorable.
methodsthis review article summarizes the epidemiological and microbiological characteristics of BSIs with a particular focus on ICU acquired BSIs (ICU-BSIs), which are usually caused by multidrug-resistant (MDR) pathogens. For this reason, their antimicrobial resistance patterns and therapeutic options have also been compiled.
resultsICU-acquired BSIs prevail in 5-7% of ICU patients.
conclusionsConsidering that prevention and treatment of sepsis is nowadays considered a global health priority by the World Health Organization, it is our obligation to invest more resources into solving or reducing the spread of these unfaithful infections. It is relevant to identify patients with risk factors that make them more susceptible to BSIs, to guarantee earlier molecular or microbiological diagnoses, and more rapidly appropriate treatment by using de-escalation strategies where possible.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.